文献速递药物相互作用特殊人群用药

药物基因组学信息改善急性入院老年患者处方实践的临床相关性

Clinical relevance of pharmacogenomic information for improving prescribing practices in acutely admitted older medical patients.
PubMed 文献 · Br J Clin Pharmacol · 2026-08-29

该研究在125例急性入院的老年内科患者中评估药物基因组学信息对处方实践的临床相关性。使用Personal Medicine Profile™检测14个药物基因,GeneYouIn PillCheck™软件进行基因型-表型翻译并识别药物-基因相互作用。结果显示50.4%患者存在药物-基因相互作用,其中46.5%被临床专家认为具有临床相关性,影响总研究人群的26.4%。

要点

  • 超过四分之一急性入院老年患者存在至少一个临床相关药物-基因相互作用。
  • 常见涉及基因包括CYP2C19、SLCO1B1、CYP2D6、CYP2C9和OPRM1。
  • 解读时需考虑营养状态和炎症等可能改变药物基因活性的因素。

核心结论

  • 超过四分之一急性入院老年患者存在一个或多个临床相关药物-基因相互作用,提示药物基因组学信息可能对改善急性期处方实践有临床效用。

研究设计与样本

  • 研究纳入125例急性入院的老年内科患者(中位年龄78.3岁;中位用药10种;中位慢性病7种),使用Personal Medicine Profile™检测分析14个药物基因,GeneYouIn PillCheck™软件进行基因型-表型翻译并识别药物-基因相互作用,生成基于患者实际用药的临床决策报告。

主要发现

  • 在125例患者中,药物基因组学检测在63例患者(50.4%)中识别出88个药物-基因相互作用。
  • 其中46.5%被临床专家认为对个体患者具有临床相关性,影响总研究人群中的33例患者(26.4%)。
  • 常见涉及的药物基因包括CYP2C19(25.0%)、SLCO1B1(25.0%)、CYP2D6(20.5%)、CYP2C9(14.8%)和OPRM1(6.8%)。
  • 常见涉及的药物包括氯沙坦(13.6%)、泮托拉唑(12.5%)、辛伐他汀(12.5%)、阿托伐他汀(11.4%)和美托洛尔(11.4%)。

临床怎么用

  • 对急性入院老年患者可考虑进行药物基因组学检测以识别临床相关药物-基因相互作用,辅助优化处方。
  • 解读药物基因组学结果时需结合营养状态和炎症等其他可能修饰药物基因活性的因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Safe prescribing and effective medication review during acute hospitalization depends on accurate information about liver and kidney function because these organs are responsible for the elimination of most medications. While estimates for kidney function are widely used, comparable markers of hepatic drug-metabolizing capacity are not routinely available. We evaluated the clinical relevance of pharmacogenomic (PGx) information for key pharmacogenes implicated in medication elimination in older adults presenting to the emergency department. METHODS: Fourteen pharmacogenes were analysed using the Personal Medicine Profile™ test. GeneYouIn PillCheck™ software performed genotype-to-phenotype translations, identified drug-gene interactions (DGIs) and generated a clinical decision report based on each patient's actual medication use. RESULTS: Among 125 acutely admitted older medical patients (median age 78.3 years; 10 medications; 7 chronic diseases), PGx testing identified 88 DGIs across 63 patients (50.4%). Of these, 46.5% were considered by clinical experts to be clinically relevant for the individual patient, affecting 33 patients (26.4%) in the total study population. Frequently implicated pharmacogenes included CYP2C19 (25.0%), SLCO1B1 (25.0%), CYP2D6 (20.5%), CYP2C9 (14.8%) and OPRM1 (6.8%), and frequently implicated medications included losartan (13.6%), pantoprazole (12.5%), simvastatin (12.5%), atorvastatin (11.4%) and metoprolol (11.4%). CONCLUSION: With more than one-quarter of acutely admitted older medical patients having one or more clinically relevant DGIs, these findings suggest that PGx information may have meaningful clinical utility for improving prescribing practices in acute care. However, interpretation in this population requires careful consideration of other factors such as nutritional status and inflammation that may modify pharmacogene activity.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Christensen LWS, Boas AK, Clausen E, et al. Clinical relevance of pharmacogenomic information for improving prescribing practices in acutely admitted older medical patients. Br J Clin Pharmacol. 2026. PMID: 42666103. doi:10.1002/bcp.70799

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。